BEAT Stock Price Chart More Charts

BEAT Price/Volume Stats

BioTelemetry, Inc. (BEAT) Company Bio

BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.

BEAT Price Forecast Based on DCF Valuation

Below please find a table outlining a discounted cash flow forecast for BEAT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Biotelemetry Inc ranked in the 96st percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 5653% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for BEAT, they are:

• The company's compound free cash flow growth rate over the past 3.7 years comes in at 2.11%; that's greater than 96.82% of US stocks we're applying DCF forecasting to.
• The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than only 24.56% of the free cash flow producing stocks we're observing.
• As a business, Biotelemetry Inc experienced a tax rate of about 13% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 60.05% of stocks generating free cash flow.

Want more companies with a valuation profile/forecast similar to that of Biotelemetry Inc? See CORT, RDY, ASRT, FVE, and USNU.